tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

APLS Stock Latest News

Apellis Pharmaceuticals: European Aspaveli Validation and Growing U.S. C3G/IC-MPGN Traction Underpin Buy Rating
RatingsApellis Pharmaceuticals: European Aspaveli Validation and Growing U.S. C3G/IC-MPGN Traction Underpin Buy Rating
2d ago
APLS
Apellis price target raised to $28 from $27 at BofA
PremiumThe Fly
Apellis price target raised to $28 from $27 at BofA
5d ago
APLS
Apellis price target lowered to $35 from $39 at Cantor Fitzgerald
PremiumThe Fly
Apellis price target lowered to $35 from $39 at Cantor Fitzgerald
5d ago
APLS
Apellis Pharmaceuticals: Syfovre and Empaveli Outperformance Plus Pipeline Upside Support Undervalued Buy Rating and $45 Target
PremiumRatings
Apellis Pharmaceuticals: Syfovre and Empaveli Outperformance Plus Pipeline Upside Support Undervalued Buy Rating and $45 Target
5d ago
APLS
Apellis Pharmaceuticals: Durable Growth Outlook and Multiple 2025–2026 Catalysts Support Buy Rating
PremiumRatings
Apellis Pharmaceuticals: Durable Growth Outlook and Multiple 2025–2026 Catalysts Support Buy Rating
5d ago
APLS
Apellis Pharmaceuticals: Empaveli Momentum, Syfovre Franchise Durability, and Multi-Indication Expansion Support Reiterated Buy and $45 Target
PremiumRatingsApellis Pharmaceuticals: Empaveli Momentum, Syfovre Franchise Durability, and Multi-Indication Expansion Support Reiterated Buy and $45 Target
5d ago
APLS
Apellis falls -17.3%
Premium
The Fly
Apellis falls -17.3%
6d ago
APLS
Apellis reports preliminary FY25 U.S. net product revenues of $689M
Premium
The Fly
Apellis reports preliminary FY25 U.S. net product revenues of $689M
6d ago
APLS
Apellis announces strategic priorities for 2026
PremiumThe Fly
Apellis announces strategic priorities for 2026
6d ago
APLS
Apellis price target lowered to $48 from $55 at Stifel
PremiumThe Fly
Apellis price target lowered to $48 from $55 at Stifel
30d ago
APLS
Apellis Pharmaceuticals: Buy Rating Affirmed Amidst European Regulatory Milestones and Long-term Growth Potential
PremiumRatings
Apellis Pharmaceuticals: Buy Rating Affirmed Amidst European Regulatory Milestones and Long-term Growth Potential
1M ago
APLS
Roth Capital healthcare analyst holds an analyst/industry conference call
PremiumThe Fly
Roth Capital healthcare analyst holds an analyst/industry conference call
1M ago
BDX
JNJ
Buy Rating for Apellis Pharmaceuticals: Strong Empaveli Launch and Long-term Syfovre Potential
PremiumRatingsBuy Rating for Apellis Pharmaceuticals: Strong Empaveli Launch and Long-term Syfovre Potential
1M ago
APLS
Apellis announces NEJM published ‘positive’ Phase 3 EMPAVELI study data
Premium
The Fly
Apellis announces NEJM published ‘positive’ Phase 3 EMPAVELI study data
2M ago
APLS
Apellis announces 5-year GALE data showing SYFOVRE delayed progression of GA
Premium
The Fly
Apellis announces 5-year GALE data showing SYFOVRE delayed progression of GA
2M ago
APLS
Promising Potential of Empaveli in Kidney Disease Treatment Drives Buy Rating for Apellis Pharmaceuticals
PremiumRatings
Promising Potential of Empaveli in Kidney Disease Treatment Drives Buy Rating for Apellis Pharmaceuticals
2M ago
APLS
Caterpillar upgraded, Elf Beauty downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Caterpillar upgraded, Elf Beauty downgraded: Wall Street’s top analyst calls
2M ago
FN
CAT
Hold Rating on Apellis Pharmaceuticals: Balancing Stagnant Revenue Growth and Market Challenges
PremiumRatings
Hold Rating on Apellis Pharmaceuticals: Balancing Stagnant Revenue Growth and Market Challenges
2M ago
APLS
Apellis initiated with a Peer Perform at Wolfe Research
PremiumThe Fly
Apellis initiated with a Peer Perform at Wolfe Research
2M ago
APLS
Apellis price target lowered to $36 from $40 at JPMorgan
PremiumThe FlyApellis price target lowered to $36 from $40 at JPMorgan
2M ago
APLS
Apellis price target lowered to $19 from $24 at Mizuho
Premium
The Fly
Apellis price target lowered to $19 from $24 at Mizuho
3M ago
APLS
Apellis Pharmaceuticals’ Earnings Call Highlights FDA Approval and Market Challenges
Premium
Company Announcements
Apellis Pharmaceuticals’ Earnings Call Highlights FDA Approval and Market Challenges
3M ago
APLS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >